Atypical hemolytic uremic syndrome and C3 glomerulopathy (dense deposit disease and C3 glomerulonephritis) are characterized inappropriate activation of the alternative complement pathway (AP). Genetic mutations affecting the AP regulating proteins (complement factor H, I, membrane co-factor protein, complement factor H related proteins) and triggers (such as infection, surgery, pregnancy, and autoimmune disease flares) result in the clinical manifestation of these diseases. A decade ago prognosis of these disease states was quite poor with the majority of patients developing end-stage renal disease. Furthermore, renal transplantation in these conditions was associated with poor outcomes due to graft loss to recurrent disease. Recent advances in targeted complement inhibitor therapy resulted in significant improvement in disease remission, renal recovery, health-related quality of life and allograft survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.